(Q24186461)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

meta-analysis

0 references

title

Milnacipran for pain in fibromyalgia in adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

2

Sheena Derry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

4

R Andrew Moore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1

Malene Cording

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Tudor Phillips

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

20 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

CD008244

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Effect of milnacipran on body weight in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Influence of trial sample size on treatment effect estimates: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Milnacipran for neuropathic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Drugs for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Fibromyalgia and neuropathic pain--differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Milnacipran for treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Gabapentin for chronic neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Duloxetine use in chronic painful conditions--individual patient data responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Worldwide epidemiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Antidepressants for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Resting state connectivity correlates with drug and placebo response in fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Pregabalin in fibromyalgia--responder analysis from individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Bad news from the brain: descending 5-HT pathways that control spinal pain processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

What is fibromyalgia, how is it diagnosed, and what does it really mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Milnacipran for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008244.PUB3

Efficacy of milnacipran in patients with fibromyalgia.

21 January 2018

1 reference

12 December 2020

Pregabalin for acute and chronic pain in adults

1 reference

12 December 2020

Milnacipran for the management of fibromyalgia syndrome.

1 reference

12 December 2020

A meta-analysis of pain response in the treatment of fibromyalgia

1 reference

12 December 2020

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

1 reference

12 December 2020

Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia

1 reference

12 December 2020

Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis.

1 reference

12 December 2020

Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials

1 reference

12 December 2020

10.1002/14651858.CD008244.PUB3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482422%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference